Search for the latest oncology news by tumour type
Inhibition of HDAC and mTOR may improve outcomes for relapsed/refractory Hodgkin lymphoma
The histone deacetylase (HDAC) inhibitor vorinostat (Zolinza) in combination with the mTOR inhibitor sirolimus (Rapamune)…